Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 278, 114220
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81803917, 81874423, 81904024)
This publication has 19 references indexed in Scilit:
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nature Reviews Drug Discovery, 2020
- Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injuryScience China Life Sciences, 2020
- China’s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak responseNature Medicine, 2020
- Efficacy of lianhuaqingwen granules in the management of chronic rhinosinusitis without nasal polypsAmerican Journal of Otolaryngology, 2020
- Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine LibraryJournal of Medicinal Chemistry, 2019
- The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune functionBMC Complementary and Alternative Medicine, 2017
- Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virusJournal of Ethnopharmacology, 2012
- Chinese Herbal Medicines for the Treatment of Type A H1N1 Influenza: A Systematic Review of Randomized Controlled TrialsPLOS ONE, 2011
- Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.2011